Tisotumab

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF) . Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963) . Tisotumab can be used for the research of solid tumors[1].

Product Specifications

CAS Number

[1418628-81-5]

Product Name Alternative

Anti-Human F3 Recombinant Antibody

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tisotumab.html

Purity

99.33

Solubility

10 mM in DMSO

Smiles

[Tisotumab]

Molecular Weight

(144.66 kDa)

References & Citations

[1]Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22 (5) :609-619.|[2]Takao S, et al. Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies. Cancer Immunol Immunother. 2025 Jan 3;74 (2) :48.